Since inferior biomimetic fabrication and anti-thrombosis process always lead to the implantation failure of artificial vascular grafts, the development of bioactive platform which can promote endothelialization is fundamental in the research for blood vessel substitutes to overcome the low-efficiency or hyperplasia. To solve the limitation of insufficient autologous sources of small blood vessels, this study prepared a tri-layer small diameter vascular based on citrate, followed by covalently immobilizing of specific peptides to achieve cells enrichment. The natural carbohydrate of carboxymethyl chitosan is creatively used as the inner layer of tubular graft, thus exerting the anti-thrombosis effect. Moreover, the gastrodin coating was employed to alleviate the inflammation response and increase the safety of this surgically implanted vascular scaffold. The synthesis process was characterized, its biocompatibility, hierarchically cell induction capacity, anticoagulant effect and the ability to promote neovascularization were evaluated. In such way, we hope to prepare a biodegradable small-diameter artificial vascular for the clinical application.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11609477 | PMC |
http://dx.doi.org/10.1016/j.bioactmat.2024.11.010 | DOI Listing |
Int J Mol Sci
December 2024
MTA-SE Lendület "Momentum" Diabetes Research Group, 1083 Budapest, Hungary.
Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease. Current treatments for DKD do not halt renal injury progression, highlighting an urgent need for therapies targeting key disease mechanisms. Our previous studies demonstrated that activating the Sigma-1 receptor (S1R) with fluvoxamine (FLU) protects against acute kidney injury by inhibiting inflammation and ameliorating the effect of hypoxia.
View Article and Find Full Text PDFJ Clin Med
December 2024
Division of Nephrology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Ratchathewi, Bangkok 10400, Thailand.
Given the significant impact of delayed graft function (DGF) on transplant outcomes, the aim of this study was to develop and validate machine learning (ML) models capable of predicting the risk of DGF in deceased-donor kidney transplantation (DDKT). This retrospective cohort study was conducted using clinical and histopathological data collected between 2018 and 2022 at Ramathibodi Hospital from DDKT donors, recipients, and post-implantation time-zero kidney biopsy samples to develop predictive models. The performance of three ML models (neural network, random forest, and extreme gradient boosting [XGBoost]) and traditional logistic regression on an independent test data set was evaluated using the area under the receiver operating characteristic curve (AUROC) and Brier score calibration.
View Article and Find Full Text PDFBiomedicines
December 2024
Area of Physiology, Department of Health Sciencies, University of Jaen, 23071 Jaen, Spain.
: Interstitial fibrosis/tubular atrophy in kidney transplantation is an unspecific lesion induced by immune and non-immune factors, which determines the progression of chronic kidney disease. Hydroxyproline is an imino acid that is part of the molecule of collagen. The aim of this study was to assess hydroxyproline in urine microvesicles as a marker of fibrosis in the renal transplant patient.
View Article and Find Full Text PDFInt J Stem Cells
January 2025
Biomedical Research Center, Asan Institute for Life Sciences, Seoul, Korea.
Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease worldwide. Despite advancements in various treatments, the prevalence of DKD continues to rise, leading to a significant increase in the demand for dialysis and kidney transplantation. This study aimed to evaluate the effects of a Small cell+Ultra Potent+Scale UP cell (SMUP-Cell), a type of human umbilical cord blood-derived mesenchymal stem cell, on DKD in the db/db mouse model of type 2 diabetes mellitus.
View Article and Find Full Text PDFCryobiology
January 2025
Reproductive Medical Center of Nanning Second People's Hospital, Nanning, Guangxi 530031, China. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!